Business Context and Reporting Period
Company: Indaptus Therapeutics, Inc. (INDP)
Filing Type: Form 8-K (Current Report)
Report Date: February 26, 2026
Event: Special Meeting of Stockholders held to approve proposals related to a December 2025 investment transaction with David E. Lazar and corporate governance changes.
Key Financial Metrics and Capital Structure
Investment Transaction:
- Investor: David E. Lazar
- Securities Purchased: 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock.
- Purchase Price: $6.00 per share.
- Aggregate Gross Proceeds: $6.0 million.
- Conversion Impact: Upon full conversion, the Preferred Stock is issuable into 111.0 million shares of common stock, representing approximately 96.4% of the total shares outstanding on a fully diluted basis.
Financial Performance: The filing text does not provide specific revenue, profit, cash flow, margin, or debt metrics for the reporting period.
Material Changes and Corporate Actions
Changes in Control and Board Composition:
- Board Shift: Jerome Jabbour and Matthew McMurdo were elected as directors. Combined with existing members and Mr. Lazar (Chairman), Mr. Lazar's nominees now constitute a majority of the nine-member Board following the resignations of Mark Gilbert and Michael Newman.
- Ownership Concentration: The conversion of Preferred Stock grants Mr. Lazar significant voting power, representing ~96.4% of fully diluted common stock.
Charter Amendments Approved:
- Authorized Stock Increase: Increased authorized common stock from 200,000,000 to 1,000,000,000 shares to facilitate future strategic transactions or equity issuances.
- Reverse Stock Split Authority: Granted the Board authority to effect up to two reverse stock splits with an aggregate ratio between 1-for-2 and 1-for-199. The specific ratio and timing remain at the Board's discretion.
- Written Consent: Amended the Charter to permit stockholder action via written consent in lieu of a meeting.
Outlook, Risks, and Management Commentary
Strategic Outlook:
- The Company intends to pursue a "Post-Investment Transaction," defined as an investment in or acquisition of an operating business (Target Company).
- The increase in authorized shares is intended to provide flexibility for this strategic pursuit and future equity awards.
Risks and Contingencies:
- Dilution: The conversion of Preferred Stock results in a massive increase in outstanding shares, significantly diluting existing common stockholders.
- Reverse Stock Split Uncertainty: While approved, the specific ratio of the reverse stock split has not been determined and may impact share price and liquidity.
- Control Risk: Mr. Lazar's nominees now hold a majority of the Board, and his convertible shares represent the vast majority of the fully diluted capitalization.
Investor Verification Checklist
- Conversion Terms: Verify the exact conversion mechanics and any anti-dilution provisions attached to the Series AA and Series AAA Preferred Stock.
- Reverse Stock Split Ratio: Monitor subsequent disclosures for the Board's determination of the specific reverse stock split ratio (1-for-2 to 1-for-199 range).
- Target Company Details: Review future filings for specifics regarding the "Target Company" and the structure of the proposed acquisition or investment.
- Liquidity Position: Assess the Company's cash runway post-$6.0 million raise relative to the costs of the planned strategic transaction.
- Board Independence: Evaluate the independence of the new Board majority given the concentration of control with Mr. Lazar.